The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
Authors
Keywords
-
Journal
Virology Journal
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-03
DOI
10.1186/s12985-023-02220-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
- (2022) ChuanLiang Cui et al. Journal for ImmunoTherapy of Cancer
- Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
- (2022) Alexander N. Shoushtari et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
- (2022) Jason A. Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
- (2022) Julia Katharina Schwarze et al. Journal for ImmunoTherapy of Cancer
- Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
- (2022) Song Y Park et al. Journal for ImmunoTherapy of Cancer
- T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model
- (2021) Emma H. A. Stahlie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
- (2021) Julia Maria Ressler et al. Journal for ImmunoTherapy of Cancer
- Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
- (2021) Josep Malvehy et al. Journal for ImmunoTherapy of Cancer
- The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
- (2021) Matthew J. Page et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma
- (2021) Robert H. I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors in melanoma
- (2021) Matteo S Carlino et al. LANCET
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
- (2021) R. Dummer et al. NATURE MEDICINE
- Oncolytic Viruses for the Treatment of Metastatic Melanoma
- (2020) Megan H. Trager et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec
- (2020) Claire Audrey-Bayan et al. MELANOMA RESEARCH
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
- (2020) Sreya Bagchi et al. Annual Review of Pathology-Mechanisms of Disease
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
- (2019) Robert H.I. Andtbacka et al. EBioMedicine
- Design and application of oncolytic viruses for cancer immunotherapy
- (2019) Erkko Ylösmäki et al. CURRENT OPINION IN BIOTECHNOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
- (2018) Lillian Sun et al. Journal for ImmunoTherapy of Cancer
- A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients
- (2018) Margarita Garcia et al. HUMAN GENE THERAPY
- The Role of Oncolytic Viruses in the Treatment of Melanoma
- (2018) Claire-Audrey Y. Bayan et al. Current Oncology Reports
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
- (2018) Carmela Passaro et al. CLINICAL CANCER RESEARCH
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
- (2016) Praveen K. Bommareddy et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma
- (2016) B. Curti et al. ANNALS OF ONCOLOGY
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
- (2016) Robert H. I. Andtbacka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunovirotherapy with measles virus strains in combination with anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment
- (2016) Jayson Hardcastle et al. NEURO-ONCOLOGY
- Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
- (2016) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Oncolytic Viruses: Therapeutics With an Identity Crisis
- (2016) Caroline J. Breitbach et al. EBioMedicine
- Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Resultsin vitro, in rodents and in humans
- (2015) Simona Bramante et al. INTERNATIONAL JOURNAL OF CANCER
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- (2014) James Larkin et al. LANCET ONCOLOGY
- Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma
- (2012) Evanthia Galanis et al. MOLECULAR THERAPY
- A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
- (2011) Tae-Ho Hwang et al. MOLECULAR THERAPY
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started